Skip to main content
Lytix Biopharma AS logo

Lytix Biopharma AS — Investor Relations & Filings

Ticker · LYTIX ISIN · NO0010405780 LEI · 549300NXMIMRSBCDZO71 OL Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country NO Norway
Listing OL LYTIX

About Lytix Biopharma AS

https://www.lytixbiopharma.com/

Lytix Biopharma AS is a clinical-stage immuno-oncology company that develops a proprietary platform of oncolytic molecules for cancer treatment. The company's technology is based on molecules designed to selectively target and lyse cancer cell membranes. This process releases a broad spectrum of tumor antigens, which in turn stimulates a patient's immune system to recognize and attack the cancer, effectively turning immunologically "cold" tumors "hot". Its lead drug candidate, ruxotemitide, is being evaluated in clinical trials as a neoadjuvant treatment for various solid tumors, including melanoma and basal cell carcinoma.

Recent filings

Filing Released Lang Actions
Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab
Regulatory Filings Classification · 15% confidence The document is a corporate press release announcing Phase II clinical data for a drug in combination with pembrolizumab. It does not contain financial results, management changes, voting results, or any formal regulatory report or proxy materials. It is not a presentation (IP), a quarterly or annual report (IR/10-K), or any of the specialized filings. Therefore, the most appropriate classification under the fallback category for general corporate announcements is “Regulatory Filings (RNS).”
2026-06-01 English
Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances - Attachment: 2026-Q1 - Lytix Biopharma - Quarterly Presentation - Final.pdf
Investor Presentation Classification · 92% confidence The document is a slide deck titled “Q1 Earnings Presentation” dated May 21, 2026. It contains an overview of the company’s platform, pipeline data, clinical trial results, and first-quarter business and financial highlights. This is clearly an investor-facing presentation rather than a standalone press release or transcript. It does not contain full financial statements typical of interim reports (IR) nor is it a press release summary (ER). It is a detailed investor presentation, fitting ‘Investor Presentation’ (IP).
2026-05-21 English
Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances
Earnings Release Classification · 90% confidence The document is a press release announcing Lytix Biopharma’s first quarter 2026 results with key development and financial highlights (e.g., cash, operating expenses) and webcast details. It is an initial announcement of quarterly results rather than a full interim report with detailed financial statements. This matches an Earnings Release (ER). Q1 2026
2026-05-21 English
Lytix Biopharma: Invitation to the Q1 2026 Results Presentation
Report Publication Announcement Classification · 86% confidence The document is a press release inviting investors to a live webcast presentation of the company’s upcoming Q1 2026 financial results. It does not contain any actual financial data or the full presentation itself, but rather announces the timing, format, and access details for the report release. Under the “menu vs. meal” rule, this is an announcement regarding the publication/timing of a report, not the report itself.
2026-05-15 English
New Phase II Study Data from Lytix Biopharma’s Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma
Regulatory Filings Classification · 90% confidence The document is a press release announcing new Phase II clinical study data to be presented at a scientific conference (SID 2026). It discusses clinical trial results and upcoming presentation details but does not contain comprehensive financial data, regulatory filings, or detailed financial reports. It is not an earnings release, annual report, or any regulatory filing. It is an announcement of scientific data presentation, which does not fit into the typical financial or regulatory filing categories. The closest relevant category is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2026-05-06 Norwegian
Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026
Regulatory Filings Classification · 65% confidence The document is a short press release announcing Phase II trial results being presented at the ASCO conference. It does not contain financial results, governance changes, management discussion, or detailed investor materials, nor is it a formal report or regulatory filing like a 10-K or interim report. It is not announcing a shareholder vote, dividend, or financing, but rather a scientific presentation. This does not match any specific category except as a general announcement. Therefore, it falls into the fallback category of Regulatory Filings (RNS).
2026-04-21 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.